The growth-response of human tumor-cell lines expressing the EGF receptor to treatment with EGF and or mabs that block ligand-binding.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  International Journal of Oncology

• Publication date

  1993-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/IJO.3.2.237PMID 21573354
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells.

  1993cited by this paper
• The physiology of transforming growth factor-alpha.

  1992cited by this paper
• Characterization of the a431 tumor xenograft as an invivo model for testing epidermal growth factor-receptor antagonists.

  1992cited by this paper
• Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly.

  1991cited by this paper
• Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer

  1991cited by this paper
• Epidermal growth factor receptor-reactive monoclonal antibodies: xenograft antitumor activity alone and as drug immunoconjugates.

  1991cited by this paper
• Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers.

  1991cited by this paper
• The epidermal growth factor. A review of structural and functional relationships in the normal organism and in cancer cells.

  1990cited by this paper
• Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

  1990cited by this paper
• Rat monoclonal antibodies to the external domain of the product of the C‐erbB‐2 proto‐oncogene

  1990cited by this paper
• Epidermal growth factor.

  1990cited by this paper
• Transmembrane TGF-alpha precursors activate EGF/TGF-alpha receptors.

  1989cited by this paper
• Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells.

  1989cited by this paper
• Isolation and characterization of A-431 cells that retain high epidermal growth factor binding capacity and respond to epidermal growth factor by growth stimulation.

  1988cited by this paper
• Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants

  1987cited by this paper
• Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors.

  1987cited by this paper
• Stimulation by EGF of the growth of EGF receptor‐hyperproducing tumor cells in athymic mice

  1987cited by this paper
• High incidence of egf receptor hyperproduction in esophageal squamous‐cell carcinomas

  1987cited by this paper
• Derivation and assay of biological effects of monoclonal antibodies to epidermal growth factor receptors.

  1987cited by this paper
• Over‐expression of the EGF receptor is a hallmark of squamous cell carcinomas

  1986cited by this paper
• Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas.

  1986cited by this paper
• Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice.

  1986cited by this paper
• Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture.

  1986cited by this paper
• Epidermal growth factor receptors on human breast cancers

  1985cited by this paper
• Autocrine growth factors and cancer

  1985cited by this paper
• The EGF receptor: structure, regulation and potential role in malignancy.

  1985cited by this paper
• Autocrine, paracrine and endocrine mechanisms of growth control.

  1985cited by this paper
• MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF.

  1985cited by this paper
• Epidermal growth factor stimulates the growth of A431 tumors in athymic mice.

  1985cited by this paper
• Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells.

  1984cited by this paper
• Human squamous cell lung cancers express increased epidermal growth factor receptors.

  1984cited by this paper
• Expression of epidermal growth factor receptors in human brain tumors.

  1984cited by this paper
• The production of hybridomas from the gut associated lymphoid tissue of tumour bearing rats. I. Mesenteric nodes as a source of IgG producing cells.

  1984cited by this paper
• Analysis of morphology and receptor metabolism in clonal variant A431 cells with differing growth responses to epidermal growth factor

  1983cited by this paper
• Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

  1983cited by this paper
• Altered epidermal growth factor (EGF)-stimulated protein kinase activity in variant A431 cells with altered growth responses to EGF.

  1982cited by this paper
• Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture

  1982cited by this paper
• A monoclonal antibody to the human epidermal growth factor receptor

  1982cited by this paper
• Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck.

  1981cited by this paper
• Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

  1978cited by this paper
• Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431.

  1978cited by this paper

• Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers.

  2018cites this paper
• Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment‐induced reduction in EGFR, pEGFR, and pSrc

  2017cites this paper
• Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.

  2016cites this paper
• Understanding the Role of EGFR in the Treatment of Head and Neck Squamous Cell Carcinoma

  2014cites this paper
• Identification of Tumor Cell- and Stroma Derived Biomarkers of Treatment Response in Head and Neck Cancer

  2013cites this paper
• Archive of SID Production and Characterization of a Monoclonal Antibody against an Antigen on the Surface of Non-Small Cell Carcinoma of the Lung

  2007cites this paper
• Characterizing and engineering antibodies against the epidermal growth factor receptor

  2007cites this paper
• Production and characterization of a monoclonal antibody against an antigen on the surface of non-small cell carcinoma of the lung.

  2007cites this paper
• Tumor models for preclinical development of targeted agents.

  2005cites this paper
• Cancer Biology and Hormesis: Human Tumor Cell Lines Commonly Display Hormetic (Biphasic) Dose Responses

  2005cites this paper
• Molecular therapy of head and neck cancer

  2005cites this paper
• The Expression Pattern and Prognostic Value of Human Epidermal Growth Factor Receptor-2 and Microvessel Density in Human Colorectal Cancer.

  2004cites this paper
• Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments.

  2004cites this paper
• The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma.

  2002cites this paper
• Angiogenesis and matrix metalloproteinases in non-small cell lung cancer

  2000cites this paper
• Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.

  2000cites this paper
• Epidermal Growth Factor-like Ligands Differentially UpRegulate Matrix Metalloproteinase 9 in Head and Neck Squamous Carcinoma Cells 1

  2000cites this paper
• Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

  1999influential citation
• Escape of autocrine ligands into extracellular medium: experimental test of theoretical model predictions.

  1998cites this paper
• Anti‐EGFR monoclonal antibodies which act as EGF, TGFα, HB‐EGF and BTC antagonists block the binding of epiregulin to EGFR‐expressing tumours

  1998cites this paper
• EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.

  1998cites this paper
• Inhibition of growth in oral squamous carcinoma cells by cyclopentenone prostaglandins: comparison with chemotherapeutic agents.

  1997cites this paper
• EGF Receptor in Tumor Growth and Progression

  1997cites this paper
• Quantification of receptor-ligand interactions on bioengineered autocrine call system : a comparision of theory and experiments

  1997cites this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cites this paper
• Preclinical Studies with Human Tumour Xenografts Using Rat Monoclonal Antibodies Directed Against the Epidermal Growth Factor Receptor

  1997cites this paper
• Monoclonal antibodies directed against the EGF receptor show differential bindings of amphiregulin and EGF to the EGF receptor.

  1997cites this paper
• Targeting the epidermal growth factor receptor for therapy of carcinomas.

  1996cites this paper
• Monoclonal antibodies to the EGF receptor act as betacellulin antagonists.

  1996cites this paper
• Molecular/cell engineering approach to autocrine ligand control of cell function

  1995cites this paper
• The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.

  1995cites this paper
• Immunotherapy with antibodies to the EGF receptor

  1994cites this paper
• Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor.

  1994cites this paper
• The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review).

  1994cites this paper
• Domain-level Antibody Epitope Mapping through Yeast Surface Display of Epidermal Growth Factor Receptor Fragments

  year unknowncites this paper